Share
March 12, 2026 – (Investorideas.com
Newswire) Reports Breaking Medical Tech Stock news -
Aethlon Medical, Inc.
(Nasdaq: AEMD), a medical therapeutic company focused on developing products to
treat cancer and life-threatening infectious diseases.
The stock gained today on news, currently trading at 1.7300+0.0794
(+4.81%), with a day’s high of $1.94 on a volume of over
859,000 shares as of this report.
Aethlon Medical, Inc.
(Nasdaq: AEMD) today announced that it is evaluating a range of strategic
opportunities and has engaged Maxim Group LLC (“Maxim”)
to act as the company’s exclusive financial advisor in connection
with this process.
The Company engaged Maxim following preliminary inbound interest
regarding potential strategic opportunities. Maxim will assist the
Company in reviewing a range of potential transactions, including
partnerships, mergers, acquisitions, or other opportunities
involving the Company.
James Frakes, Chief Executive Officer and Chief Financial
Officer of Aethlon, stated, “The company continues to
execute its development activities, having completed the second
cohort of our Australian oncology trial. Safety data from that
cohort will be submitted to the independent Data Safety
Monitoring Board for review. At the same time, we are evaluating
strategic alternatives with the assistance of Maxim as part of
our ongoing efforts to assess opportunities available to the
Company and its shareholders.”
The company has not established a definitive timeline for this
evaluation and can provide no assurance that any transaction will
result from this process. The Company will pursue only those
opportunities that the Board believes are appropriate for the
Company and its shareholders.
About Maxim Group LLC
Founded in 2002, Maxim Group is a leading full-service investment
bank, securities, and wealth management firm headquartered in
Midtown Manhattan, providing a comprehensive array of financial
services, including investment banking, global institutional sales,
equity research, fixed income and derivative sales & trading,
merchant capital, private wealth management, and prime brokerage
services to a diverse range of corporate clients, institutional
investors, and high-net-worth individuals. Maxim Group is a
registered broker-dealer with the U.S. Securities and Exchange
Commission and the Municipal Securities Rulemaking Board (MSRB). To
learn more about Maxim Group, visit www.maximgrp.com.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical
device company headquartered in San Diego, California. Aethlon is
advancing the Hemopurifier, to address unmet needs in oncology and
infectious disease, using a novel platform designed to selectively
remove circulation pathogenic targets from biologic fluids.
For more information, visit
www.AethlonMedical.com
and follow the Company on LinkedIn.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing
the Hemopurifier, a clinical stage immunotherapeutic device which is
designed to combat cancer and life-threatening viral infections and
for use in organ transplantation. In human studies, the Hemopurifier
has demonstrated the removal of life-threatening viruses and in
pre-clinical studies, the Hemopurifier has demonstrated the removal of
harmful EVs from biological fluids, utilizing its proprietary
lectin-based technology. This action has potential applications in
cancer, where EVs may promote immune suppression and metastasis, and
in life-threatening infectious diseases. The Hemopurifier is a U.S.
Food and Drug Administration (FDA) designated Breakthrough Device
indicated for the treatment of individuals with advanced or metastatic
cancer who are either unresponsive to or intolerant of standard of
care therapy, and with cancer types in which EVs have been shown to
participate in the development or severity of the disease. The
Hemopurifier also holds an FDA Breakthrough Device designation and an
open Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found at
www.AethlonMedical.com.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934 that involve risks and
uncertainties. Statements containing words such as “may,” “believe,”
“anticipate,” “expect,” “intend,” “plan,” “project,” “will,”
“projections,” “estimate,” “potentially” or similar expressions
constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and
actual results may differ materially from the results anticipated in
the forward-looking statements. Risks and uncertainties include, but
are not limited to, clinical trial outcomes, regulatory approvals,
the ability to obtain additional financing, and market acceptance of
the Company’s products, as more fully described in the Company’s
filings with the Securities and Exchange Commission. These
forward-looking statements are based upon Aethlon’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. Except as may be required by law, the Company does not intend,
nor does it undertake any duty, to update this information to
reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Executive
Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan
Communications, LLC
susan@sanoonan.com
Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on
Investorideas.com More info on AEMD at Investorideas.com Visit:
https://www.investorideas.com/CO/AEMD/
Get News Alerts on Aethlon Medical
Get more biotech and medical tech news, articles, podcasts and stock directories
About Investorideas.com – Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From
breaking stock news to top-rated investing podcasts, we cover it all
Follow us on X @investorideas
Follow us on Facebook
https://www.facebook.com/Investorideas
Follow us on YouTube
https://www.youtube.com/c/Investorideas
Sign up for free stock news alerts at
Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/Disclosure: Athelon Medical, Inc. (AEMD) is
a paid featured medical tech stock on
Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of
stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and
marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific
questions.
